Tay-Sachs Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Tay-Sachs Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Tay-Sachs disease is a rare, inherited metabolic disease that mostly affects young children and involves progressive damage to and death of cells, particularly in the brain. It is caused by a mutation in the enzyme hexosaminidase A, which allows the harmful buildup of lipids (fatty materials such as oils and acids) in cells. Both parents must carry the mutated gene in order to have a child with Tay-Sachs disease. Tay-Sachs disease is part of a group of genetic disorders called the GM2 gangliosidoses
The Tay-Sachs Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Tay-Sachs Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tay-Sachs Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Tay-Sachs Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Tay-Sachs Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Tay-Sachs Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Tay-Sachs Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AceLink Therapeutics IncAllievex Corp
Azafaros BV
Duke University
Erad Therapeutics Inc
Gene Therapy Research Institution Co Ltd
Idorsia Pharmaceutical Ltd
IntraBio Ltd
JCR Pharmaceuticals Co Ltd
M6P Therapeutics
McMaster University
New Hope Research Foundation
Orphi Therapeutics Inc
Polaryx Therapeutics Inc
Retrotope Inc
Sanofi
Taysha Gene Therapies Inc
The Hospital for Sick Children
University of Massachusetts
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Tay-Sachs Disease reports